

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

218549Orig1s000

Trade Name: *ZUNVEYL delayed-release tablets, for oral use*

Generic or Proper Name: *benzgalantamine*

Sponsor: *Alpha Cognition, Inc.*

Approval Date: *July 26, 2024*

Indication: *ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.*

CENTER FOR DRUG EVALUATION AND RESEARCH

218549Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	X
Statistical Review(s)	
Clinical Microbiology / Virology Review(s)	
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

218549Orig1s000

APPROVAL LETTER



NDA 218549

NDA APPROVAL

Alpha Cognition, Inc.
c/o ProPharma Group, Inc.
Attention: Ayesha Adil
Director of Regulatory
1129 20th Street NW, Suite 600
Washington, DC 20036

Dear Ayesha Adil:

Please refer to your new drug application (NDA) dated September 27, 2023, received September 27, 2023, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zunveyl (benzgalantamine) delayed-release tablets.

This NDA provides for the use of Zunveyl (benzgalantamine) delayed-release tablets for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on July 18, 2024, as soon as they are available, but no

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 218549.**” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Zunveyl (benzgalantamine) delayed release tablets shall be:

- 24 months from the date of manufacture when stored at 20°C to 25°C in bottles.
- 6 months from the date of manufacture when stored at 20°C to 25°C in blisters.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

4666-1 Submission of the following PMC reports under a Prior Approval Supplement (PAS) to the NDA:

Investigation of root-cause of the high variability of the dissolution data for the proposed drug product.

1. A new dissolution method development report with new data evaluating the medium volume, adequate justification and evidence for using surfactant and its levels, and the discriminating ability of the proposed dissolution method.
2. Provide full in vitro dissolution profile data [including individual, mean (n=12) and %CV at each sampling time points] for all strengths of clinical and registration batches and the first six commercial batches using the revised dissolution method.
3. Propose a new set of dissolution acceptance criteria with appropriate time-point selection for the buffer stage, taking into consideration the results of method's discriminating ability.

The timetable you submitted on June 27, 2024, states that you will conduct this study according to the following schedule:

Final Report Submission: 02/28/2025

Submit clinical protocols to your IND 156154 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to

this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients/subjects entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “Postmarketing Commitment Protocol,” “Postmarketing Commitment Final Report,” or “Postmarketing Commitment Correspondence.”

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable, as Alzheimer’s disease only occurs in the adult population.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials and the Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

³ For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website⁶.

If you have any questions, contact Justine Kankam, Regulatory Project Manager, at 1-(301)-837-7650 or via email at Justine.Kankam@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Emily Freilich, MD
Director
Division of Neurology 1
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

⁶ <https://www.uspnf.com/>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

EMILY R FREILICH
07/26/2024 01:52:41 PM